RE: $23m deals mkt cap £2.2m29 Jun 2025 20:50
Daily Mail article back in Feb
On the back of the deal with pleaides
“With the Lyramid sale in progress, Roquefort’s focus shifts to assets acquired through its takeover of Oncogeni, a biotech founded by Nobel laureate Sir Martin Evans.
The company is developing treatments in two cutting-edge areas of cancer research: small interfering RNA (siRNA, or gene silencing) and mesodermal killer (MK) cells.
MK cells represent a relatively new approach to cellular medicine, engineered to destroy cancer cells and enhance the activity of the body’s natural killer cells.
Reginald believes these two programmes are the most promising in Roquefort’s pipeline.
Meanwhile, the company is in discussions with potential partners to take the assets further. Out-licensing deals of this kind can be significant value inflexion points, often involving substantial upfront and milestone payments.
Interest, according to Reginald, is strong. ‘There is a lot of excitement around both programmes,’ he says.
For investors seeking exposure to early-stage biotech, Roquefort presents an intriguing opportunity.
Its relatively modest market valuation reflects the broader challenges facing small-cap life sciences companies, but it may also offer an attractive entry point for those with the stomach to ride the irrational undulations of the UK small-cap sector.
Objectively, the Lyramid transaction is worth way in excess of Roquefort's current worth. So, effectively all the downside has been priced in (and more).
Definitely one to watch.
https://www.dailymail.co.uk/money/markets/article-14380943/SMALL-CAP-IDEA-Roquefort-finds-pharma-diamonds-rough.html
Now we have $12m deal for Oncogeni
As well as Lyramid deal $10.8m
Mkt cap £2.25m